A Phase I, Randomized, Double-blind, Multi-centre, Placebo-controlled, Dose-escalation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of AstriVax' Investigational Vaccine for the Prevention of Yellow Fever (AVX70120), and of AstriVax' Investigational Vaccine for the Prevention of Rabies (AVX70481), in Healthy Adults Aged 18 to 40 Years
Latest Information Update: 17 Jun 2025
At a glance
- Drugs AVX 70120 (Primary) ; AVX 70481 (Primary)
- Indications Rabies; Yellow fever
- Focus Adverse reactions; First in man
- Acronyms SAFYR
- Sponsors AstriVax
Most Recent Events
- 17 Jun 2025 New trial record